Multiple sclerosis-associated IL2RA polymorphism controls GM-CSF production in human TH cells. (Q50777713)

19 March 2018

title

Multiple sclerosis-associated IL2RA polymorphism controls GM-CSF production in human TH cells. (English)

1 reference

19 March 2018

0 references

2

1 reference

19 March 2018

Sandra Ammann

4

1 reference

19 March 2018

Cris Constantinescu

6

1 reference

19 March 2018

Felix J Hartmann

Felix J Hartmann

1

0 references

Ingrid Kockum

Ingrid Kockum

5

0 references

Burkhard Becher

11

Burkhard Becher

1 reference

19 March 2018

Fredrik Piehl

8

Fredrik Piehl

1 reference

19 March 2018

Tomas Olsson

9

Tomas Olsson

1 reference

19 March 2018

Bruno Gran

7

Bruno Gran

1 reference

19 March 2018

author name string

Jehan Aram

3

1 reference

19 March 2018

Laura Codarri

10

1 reference

19 March 2018

language of work or name

English

0 references

publication date

3 October 2014

1 reference

19 March 2018

published in

Nature Communications

1 reference

19 March 2018

volume

5

1 reference

19 March 2018

page(s)

5056

1 reference

19 March 2018

The genetics of multiple sclerosis: SNPs to pathways to pathogenesis

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS6056

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS6056

Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS6056

Tyrosine kinase 2 variant influences T lymphocyte polarization and multiple sclerosis susceptibility

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS6056

TNF receptor 1 genetic risk mirrors outcome of anti-TNF therapy in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS6056

Soluble IL7Rα potentiates IL-7 bioactivity and promotes autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS6056

RORγt drives production of the cytokine GM-CSF in helper T cells, which is essential for the effector phase of autoimmune neuroinflammation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS6056

The encephalitogenicity of T(H)17 cells is dependent on IL-1- and IL-23-induced production of the cytokine GM-CSF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS6056

Granulocyte macrophage colony-stimulating factor: a new putative therapeutic target in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS6056

Differential regulation of lymphokine production by distinct subunits of the T cell interleukin 2 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS6056

New insights into the regulation of T cells by gamma(c) family cytokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS6056

Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS6056

Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS6056

Risk alleles for multiple sclerosis identified by a genomewide study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS6056

Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS6056

The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS6056

How regulatory T cells work

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS6056

Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS6056

Regulatory T cell proliferative potential is impaired in human autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS6056

Mavrilimumab, a human monoclonal antibody targeting GM-CSF receptor-α, in subjects with rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase I, first-in-human study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS6056

Biased Treg/Th17 balance away from regulatory toward inflammatory phenotype in relapsed multiple sclerosis and its correlation with severity of symptoms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS6056

Matrix metalloproteinase-9 and autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS6056

Neurofilament protein in cerebrospinal fluid: a potential marker of activity in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS6056

Cell-specific protein phenotypes for the autoimmune locus IL2RA using a genotype-selectable human bioresource

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS6056

HLA-DR15-derived self-peptides are involved in increased autologous T cell proliferation in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS6056

T(H)17 cytokines in autoimmune neuro-inflammation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS6056

IL-17 and GM-CSF expression are antagonistically regulated by human T helper cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS6056

Large-scale genetic fine mapping and genotype-phenotype associations implicate polymorphism in the IL2RA region in type 1 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS6056

IL2RA genetic heterogeneity in multiple sclerosis and type 1 diabetes susceptibility and soluble interleukin-2 receptor production

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS6056

Soluble IL-2RA levels in multiple sclerosis subjects and the effect of soluble IL-2RA on immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS6056

A high-resolution HLA and SNP haplotype map for disease association studies in the extended human MHC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS6056

Intense inflammation and nerve damage in early multiple sclerosis subsides at older age: a reflection by cerebrospinal fluid biomarkers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS6056

Production of granulocyte-macrophage colony-stimulating factor by T cells is regulated by B7 and IL-1β

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS6056

GM-CSF production by autoreactive T cells is required for the activation of microglial cells and the onset of experimental autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS6056

inferred from DOI database lookup

7 January 2021

based on heuristic

MOR103, a human monoclonal antibody to granulocyte-macrophage colony-stimulating factor, in the treatment of patients with moderate rheumatoid arthritis: results of a phase Ib/IIa randomised, double-blind, placebo-controlled, dose-escalation trial

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS6056

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/NCOMMS6056

1 reference

19 March 2018

ADS bibcode

2014NatCo...5.5056H

0 references

1 reference

19 March 2018